The Albany Gazette - enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

NYSE - LSE

CMSC	0.11%	21.744	$
RIO	1.43%	101.1	$
VOD	1.17%	16.19	$
BCC	2.7%	86.6	$
RBGPF	1.08%	70.5	$
RYCEF	1.1%	20.85	$
RELX	0.14%	35.52	$
NGG	0.58%	80.88	$
CMSD	-0.73%	21.82	$
BCE	-0.09%	22.75	$
GSK	1.49%	52.96	$
JRI	1.17%	12.81	$
BTI	1.01%	59.33	$
BP	-1.44%	41.63	$
AZN	0.87%	161.42	$

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

TECHNOLOGY 02.06.2026

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9^that 4:00 PM ET

Register here

Text size:

IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET.

As part of the event, Mr. Berman will discuss the Company's recently reported IDE approval of its enVVe^® System, marking a first-ever FDA IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve.

Additionally, there will be a live question and answer session with audience participants. Mr. Berman will answer as many questions as possible in the time allowed.

A live video webcast will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will become available two hours following the live event and will be accessible for 90 days.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is currently developing the enVVe system, which includes a first-in-class non-surgical replacement venous valve being developed for the treatment of severe Deep Venous Insufficiency (DVI). The enVVe valve is designed to act as one-way valve, to help assist in propelling blood up the leg, and back to the heart and lungs. As a transcatheter delivered device, the enVVe procedure will be performed under light sedation and should not require an over-night hospital stay.

INVESTOR CONTACT:

JTC Team, LLC
Jenene Thomas
[email protected]
(908) 824-0775

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

(B.Ramirez--TAG)

Featured

Nocturnal 'coffee frog' discovered in Costa Rica

A tiny greenish, noctural frog that thrives in coffee plantations has been discovered in the Costa Rica's central Pacific region, where it also faces risks from agrochemicals used in farming.

New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results

Sponsored Programming Also Broadcasts Across Bloomberg Television in Latin America and MENA, Expanding the Global Reach of New to The Street's Featured Companies

Austrian writer Stefan Zweig, who fled Nazis, honoured in London

With its grand facade, the 1930s London mansion block looks like countless others. But one flat hides a tale of one of the darkest chapters in 20th century European history.

Military shake-up poses little threat to Ukraine's drone revolution

Zigzagging between robots, weapons and computers in his garage workshop, Ukrainian engineer Eduard Trotsenko was bubbling with excitement as he showed off his latest prototypes and dreamed of sci-fi-inspired futuristic ideas.